Natus Medical Incorporated (NASDAQ:BABY) – Research analysts at William Blair increased their FY2017 EPS estimates for Natus Medical in a note issued to investors on Wednesday. William Blair analyst B. Weinstein now anticipates that the medical equipment provider will earn $1.74 per share for the year, up from their prior forecast of $1.70. William Blair also issued estimates for Natus Medical’s Q4 2017 earnings at $0.71 EPS, Q1 2018 earnings at $0.38 EPS, Q2 2018 earnings at $0.49 EPS, Q3 2018 earnings at $0.51 EPS, Q4 2018 earnings at $0.71 EPS and FY2018 earnings at $2.08 EPS.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.02. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The firm had revenue of $122.60 million during the quarter, compared to analysts’ expectations of $122.41 million. During the same period in the previous year, the company earned $0.39 EPS. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “Natus Medical Incorporated Forecasted to Earn FY2017 Earnings of $1.74 Per Share (BABY)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/27/natus-medical-incorporated-forecasted-to-earn-fy2017-earnings-of-1-74-per-share-baby.html.

Several other brokerages have also weighed in on BABY. Zacks Investment Research lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. BidaskClub raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Natus Medical currently has an average rating of “Hold” and an average target price of $46.50.

Shares of Natus Medical (BABY) opened at 40.10 on Friday. The firm has a 50-day moving average of $37.55 and a 200 day moving average of $36.13. Natus Medical has a 52-week low of $31.65 and a 52-week high of $43.85. The stock has a market capitalization of $1.30 billion, a PE ratio of 69.50 and a beta of 0.95.

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in Natus Medical by 0.6% in the second quarter. BlackRock Inc. now owns 4,149,535 shares of the medical equipment provider’s stock worth $154,779,000 after acquiring an additional 25,340 shares during the last quarter. Vanguard Group Inc. lifted its stake in Natus Medical by 2.9% in the second quarter. Vanguard Group Inc. now owns 2,341,546 shares of the medical equipment provider’s stock worth $87,340,000 after acquiring an additional 66,676 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Natus Medical by 10.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,552,938 shares of the medical equipment provider’s stock worth $57,924,000 after acquiring an additional 151,372 shares during the last quarter. Daruma Capital Management LLC lifted its stake in Natus Medical by 13.1% in the second quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock worth $54,862,000 after acquiring an additional 169,890 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Natus Medical by 9.7% in the second quarter. Bank of New York Mellon Corp now owns 973,346 shares of the medical equipment provider’s stock worth $36,307,000 after acquiring an additional 86,192 shares during the last quarter. Institutional investors own 94.57% of the company’s stock.

In other news, Director William M. Moore sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the transaction, the director now owns 30,410 shares of the company’s stock, valued at $1,036,981. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the completion of the transaction, the director now owns 50,850 shares of the company’s stock, valued at approximately $1,788,394.50. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Earnings History and Estimates for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.